MATERIALS AND METHODS: A total of seventy patients who died in the ICU of a Level III Combined Military Hospital within a period of 2 years were studied in retrospect to review the mortality pattern.
RESULTS: Overall mortality rate was 3.58%, among which 81.43% were male and 18.57% were female. The mortality rate in geriatric patients was 12.26% and 2.84% in the age group of 12-60 years and 2.56% in below 12 years. The major causes of death were ischemic heart disease (20%), cerebrovascular disease (14.28%), and chronic obstructive pulmonary disease (10%). Highest incidence of death occurred during 1-3 days of ICU stay (34.28%) and the lowest was at 4 days to 1 week (4.28%).
CONCLUSION: Ischemic heart disease (IHD) is remaining as the most important cause of mortality in our community although many countries have succeeded in reducing the IHD mortality by a combination of lifestyle modification and improving the health-care delivery systems.
OBJECTIVE: To review ongoing trials relating to COVID-19.
METHODS: A systematic search for clinical trials was conducted in the ClinicalTrials.gov database up to April 12, 2020. A total of 339 trials relating to COVID-19 were analyzed and key information on each trial was recorded.
RESULTS: Most of the trials were being conducted in the United States and completion of most of them was expected by May 2020. They were mostly on drugs and treatment, while a minority were on diagnostic tests. The analysis showed that hydroxychloroquine was investigated in most of the trials. The trials identified were categorized into five classes: a) diagnostic tests; b) therapeutics; c) biologics and vaccines; d) devices and products; and e) others.
CONCLUSION: The trials identified have potential against COVID-19 that can be applied in treatment processes after the necessary investigations and experiments. Additionally, the items identified were organized in a proper way, which can assist in current research activities.